Human Genome Epidemiology Literature Finder
|
Records 1 - 26 (of 26 Records) |
| Query Trace: Hyperplasia and SRD5A2[original query] |
|---|
| A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. British journal of cancer 2001 May 84 (10): 1344-7. Mononen N, Ikonen T, Syrjäkoski K, Matikainen M, Schleutker J, Tammela T L, Koivisto P A, Kallioniemi O |
| Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. The Prostate 2002 Jul 52 (2): 130-8. Schatzl Georg, Madersbacher Stephan, Gsur Andrea, Preyer Martin, Haidinger Gerald, Haitel Andrea, Vutuc Christian, Micksche Michael, Marberger Micha |
| 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002 Jun 12 (4): 307-12. Söderström Torbjörn, Wadelius Mia, Andersson Swen-Olov, Johansson Jan-Erik, Johansson Sara, Granath Fredrik, Rane Ande |
| Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. European journal of endocrinology / European Federation of Endocrine Societies 2002 Oct 147 (4): 479-84. Azzouzi Abdel-Rahmene, Cochand-Priollet Beatrix, Mangin Philippe, Fournier Georges, Berthon Philippe, Latil Alain, Cussenot Olivi |
| Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. The Journal of urology 2003 Jun 169 (6): 2378-81. Li Zhenhua, Habuchi Tomonori, Mitsumori Kenji, Kamoto Toshiyuki, Kinoshitu Hidefumi, Segawa Takehiko, Ogawa Osamu, Kato Tetsu |
| Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH. The Prostate 2005 Mar 62 (4): 380-7. Roberts Rosebud O, Bergstralh Erik J, Farmer Sara A, Jacobson Debra J, McGree Michaela E, Hebbring Scott J, Cunningham Julie M, Anderson Sarah A, Thibodeau Stephen N, Lieber Michael M, Jacobsen Steven |
| A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. The pharmacogenomics journal 2004 4 (4): 251-9. Klotsman M, Weinberg C R, Davis K, Binnie C G, Hartmann K |
| The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. European urology 2005 Oct 48 (4): 679-85. Giwercman Yvonne L, Abrahamsson Per-Anders, Giwercman Aleksander, Gadaleanu Virgil, Ahlgren Gör |
| [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer]. Zhonghua yi xue za zhi 2005 May 85 (19): 1319-21. Tong Ming, Ai Jun-kui, Yuan Yi-ming, Yin Yi, Zhou Li-qun, Xin Dian-qi, Li Ming, Na Yan-q |
| Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urologic oncology 0 23 (4): 246-53. Salam Muhammad T, Ursin Giske, Skinner Eila C, Dessissa Tesfaye, Reichardt Juergen K |
| [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery] 2004 Dec 42 (24): 1493-6. Tong Ming, Xu Zhong, Ai Jun-kui, Yuan Yi-ming, Yin Yi, Wang Jun-qi, Li Hong-wei, Liu Jian-he, Xin Dian-qi, Zhou Li-qun, Li Ming, Na Yan-q |
| Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer genetics and cytogenetics 2008 Sep 185 (2): 78-85. Sobti R C, Gupta L, Singh S K, Seth A, Kaur P, Thakur |
| Joint effects of inflammation and androgen metabolism on prostate cancer severity. International journal of cancer. Journal international du cancer 2008 Sep 123 (6): 1385-9. Rebbeck Timothy R, Rennert Hanna, Walker Amy H, Panossian Saarene, Tran Teo, Walker Kyle, Spangler Elaine, Patacsil-Coomes Margerie, Sachdeva Rajeev, Wein Alan J, Malkowicz S Bruce, Zeigler-Johnson Charni |
| Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. Cancer letters 2008 Sep 268 (2): 340-7. Das Kakoli, Cheah Peh Yean, Lim Pei Li, Zain Yasmin Bte Mohad, Stephanie Fook-Chong, Zhao Yi, Cheng Christopher, Lau Web |
| Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. Journal of andrology 0 30 (6): 703-10. Rajender Singh, Vijayalakshmi Krishnaswamy, Pooja Singh, Madhavi Sakhamuri, Paul Solomon F D, Vettriselvi V, Shroff Sunil, Singh Lalji, Thangaraj Kumarasa |
| Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pacific journal of cancer prevention : APJCP 2011 12 (3): 731-3. Izmirli Muzeyyen, Arikan Burhan, Bayazit Yildirim, Alptekin Dav |
| [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer]. Zhonghua nan ke xue = National journal of andrology 2010 Nov 16 (11): 990-3. Tong Ming, Jin Yan-Yang, Li Gang, Liu Si-Ming, Ji Chun-Do |
| SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5a-reductase inhibitors and a-adrenergic receptor antagonists. The Journal of urology 2013 Mar . Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J |
| Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men. Asian Pacific journal of cancer prevention : APJCP 2014 15 (3): 1255-62. El Ezzi Asmahan Ali, Zaidan Wissam Rateeb, El-Saidi Mohammed Ahmed, Al-Ahmadieh Nabil, Mortenson Jeffrey Benjamin, Kuddus Ruhul Haq |
| Genetic polymorphism in sex hormone metabolism and prostate cancer risk. Genetics and molecular research : GMR 2015 14 (3): 7326-34. Ersekerci E, Sofikerim M, Taheri S, Demirtas A, Halis |
| SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer. Asian Pacific journal of cancer prevention : APJCP 2015 16 (3): 1033-6. Choubey Vimal Kumar, Sankhwar Satya Narayan, Carlus S Justin, Singh Anand Narayan, Dalela Divakar, Thangaraj Kumarasamy, Rajender Sin |
| Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients. Turkish journal of medical sciences 2016 46 (3): 626-40. Kachakova Darina, Mitkova Atanaska, Popov Elenko, Beltcheva Olga, Vlahova Alexandrina, Dikov Tihomir, Christova Svetlana, Mitev Vanio, Slavov Chavdar, Kaneva Rad |
| Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis. Frontiers in physiology 2017 8 688. Zeng Xian-Tao, Su Xin-Jun, Li Sheng, Weng Hong, Liu Tong-Zu, Wang Xing-Hu |
| Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels. International journal of environmental research and public health 2017 Oct 14 (11): . Ry? Aleksandra, Rotter Iwona, Grzywacz Anna, Ma?ecka Iwona, Skonieczna-?ydecka Karolina, Grzesiak Katarzyna, S?ojewski Marcin, Szyli?ska Aleksandra, Sipak-Szmigiel Olimpia, Piasecka Ma?gorzata, Walczakiewicz Kinga, Laszczy?ska Mar |
| Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncology letters 2020 9 20 (5): 261. Delgado-Balderas Jesus Rolando, Gallardo-Blanco Hugo Leonid, Yee-De León Juan Felipe, Rivas-Estilla Ana Maria, Soto-García Brenda, Aráiz-Hernández Diana, Garza-Guajardo Raquel, Náñez-Marín Melissa, Hernández-Barajas David, García-Bailón Aldo Missael, Vízcarra-Mata Guillermo, Ocaña-Munguía Marco Alberto, Gómez-Guerra Lauro Salvador, Sánchez-Domínguez Celia Nohe |
| Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population. International journal of clinical and experimental pathology 2020 1 10 (8): 8660-8676. Zhang Lin-Lin, Song Yu, He Ling-Ling, Chen Guo-Qiang, Fu Ji-Cheng, Liu Lei, Xi Bao, Wang L |
- Page last reviewed:Feb 1, 2024
- Content source: